title: Vincristine-resistant Kasabach-Merritt phenomenon successfully treated with low-dose radiotherapy.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Masaei
authors.initials: M
authors.lastname: Onuma
authors.forename: Chung Y
authors.initials: CY
authors.lastname: Looi
authors.forename: Yuka
authors.initials: Y
authors.lastname: Saito
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kitazawa
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Niizuma
authors.forename: Takeshi
authors.initials: T
authors.lastname: Rikiishi
authors.forename: Osamu
authors.initials: O
authors.lastname: Sakamoto
authors.forename: Yoji
authors.initials: Y
authors.lastname: Sasahara
authors.forename: Satoru
authors.initials: S
authors.lastname: Kumaki
authors.forename: Mika
authors.initials: M
authors.lastname: Watanabe
authors.forename: Shigeko
authors.initials: S
authors.lastname: Ushio
authors.forename: Shigeru
authors.initials: S
authors.lastname: Tsuchiya
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000628:therapy; D018324:Hemangioma, Capillary / Q000097:blood / Q000628:therapy; D006801:Humans; D007231:Infant, Newborn; D059885:Kasabach-Merritt Syndrome; D008297:Male; D011879:Radiotherapy Dosage; D014750:Vincristine / Q000008:administration & dosage*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine